Protagonist Therapeutics (PTGX) vs Summit Therapeutics (SMMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Protagonist Therapeutics (PTGX) has outperformed Summit Therapeutics (SMMT) over the past year, gaining 42.2% versus a loss of 38.5%. Over five years, PTGX leads with a +265.0% price change compared with +92.8% for SMMT. Summit Therapeutics is the larger company by market cap ($7.96 billion vs $7.92 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PTGX | SMMT |
|---|---|---|
| Share price | $121.40 | $9.95 |
| Market cap | $7.92B | $7.96B |
| 1-day change | -2.11% | -5.87% |
| YTD return | +39.00% | -43.11% |
| 1-year return | +42.15% | -38.54% |
| 5-year return | +265.00% | +92.83% |
| P/E ratio (TTM) | 25.67 | — |
| Forward P/E | 348.79 | — |
| EPS (TTM) | $4.73 | $-1.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $46.02M | — |
| Revenue growth (YoY) | -89.41% | — |
| Net income (latest FY) | $-130.15M | $-1.08B |
| Operating margin | -343.63% | — |
| Net margin | -282.83% | — |
| 52-week high | $160.81 | $29.23 |
| 52-week low | $77.00 | $9.89 |
| Distance from 52-week high | -24.51% | -65.96% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +50.21% | +189.15% |
| Average volume | 668.45K | 6.68M |
| Shares outstanding | 65.27M | 799.76M |
| Employees | 149 | 265 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTGX has outperformed SMMT by 80.7 percentage points over the past year.
About Protagonist Therapeutics
PTGX stock →Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 149 employees
About Summit Therapeutics
SMMT stock →Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
Health Care · Biotechnology: Pharmaceutical Preparations · 265 employees
PTGX vs SMMT FAQ
Which is bigger, Protagonist Therapeutics or Summit Therapeutics?
Summit Therapeutics (SMMT) is larger, with a market capitalization of $7.96B compared with $7.92B for Protagonist Therapeutics (PTGX).
Which stock has performed better over the past year, PTGX or SMMT?
PTGX returned +42.15% over the past 12 months, compared with -38.54% for SMMT (price return, excluding dividends). Past performance does not predict future results.
Are Protagonist Therapeutics and Summit Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.